LeMaitre Vascular Inc (LMAT)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.79B
Last updated: Nov 17, 2026 at 11:06 AM ET
LeMaitre Vascular Inc (LMAT) Stock Forecast
Analysts expect LeMaitre Vascular (LMAT) to earn $2.81 per share in the fiscal year ending Dec 31, 2026, on revenue of $276.03M. Of 8 analysts, 4 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 8 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 2 | 25.0% |
| Hold | 4 | 50.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 12.1% and revenue estimates rise 9.9%.
- Fiscal year ending Dec 31, 2026
- $2.81
- EPS consensus, revenue $276.03M
- Fiscal year ending Dec 31, 2027
- $3.15
- EPS consensus, revenue $303.43M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.81 | $2.78 to $2.88 | 8 | $276.03M | $275.80M to $276.50M | 8 |
| Dec 31, 2027 | $3.15 | $2.97 to $3.30 | 8 | $303.43M | $299.00M to $307.00M | 8 |
Quarterly Estimates
The EPS consensus rises from $0.74 for the quarter ending Dec 31, 2026 to $0.76 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.74 | $0.71 to $0.78 | 10 | $72.48M | $69.46M to $74.91M | 10 |
| Mar 31, 2027 | $0.76 | $0.74 to $0.77 | 5 | $73.20M | $73.00M to $73.41M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 16 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 8 |
| Fiscal year ending Dec 31, 2027 | 0 | 7 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.4% from $2.88.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.81 | $2.88 | $2.88 | $2.88 | $2.88 | -2.4% |
| Fiscal year ending Dec 31, 2027 | $3.15 | $3.18 | $3.18 | $3.18 | $3.20 | -1.6% |
| Quarter ending Mar 31, 2027 | $0.76 | $0.76 | $0.76 | $0.76 | $0.76 | -0.9% |
Frequently Asked Questions About LMAT
What is the LMAT stock forecast?
Consensus analyst estimates put LeMaitre Vascular's EPS at $2.81 for the fiscal year ending Dec 31, 2026, on revenue of $276.03M. The consensus rating from 8 analysts is Buy.
How do analysts rate LMAT stock?
Of 8 analysts covering LeMaitre Vascular, 2 rate it Strong Buy, 2 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LMAT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.81, with estimates from $2.78 to $2.88 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.15, with estimates from $2.97 to $3.30 from 8 analysts.
What revenue do analysts expect from LeMaitre Vascular next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $276.03M, with estimates from $275.80M to $276.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $303.43M, with estimates from $299.00M to $307.00M.
How many analysts cover LMAT?
8 analysts rate LeMaitre Vascular stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LMAT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts